Is the Treponema pallidum antibody particle agglutination (TP‑PA) test a treponemal assay, and does it remain positive for life after adequate treatment?

TP-PA Test Classification and Persistence After Treatment

The Treponema pallidum Particle Agglutination (TP-PA) test is a treponemal test, and yes, it typically remains positive for life even after adequate treatment 1.

Test Classification

The TP-PA is definitively classified as a treponemal test, not a nontreponemal test 1. The CDC guidelines explicitly categorize serologic tests for syphilis into two types:

• Nontreponemal tests: VDRL and RPR
• Treponemal tests: FTA-ABS, MHA-TP, and TP-PA 1

The TP-PA detects antibodies specific to Treponema pallidum antigens, which distinguishes it from nontreponemal tests that detect antiphospholipid antibodies produced in response to cellular damage from syphilis infection 2.

Persistence After Treatment

Most patients who have reactive treponemal tests will have reactive tests for the remainder of their lives, regardless of treatment or disease activity 1, 3. This applies to all treponemal tests including TP-PA.

Important Nuances:

• 15-25% exception: Patients treated during primary stage syphilis may revert to being serologically nonreactive after 2-3 years 1, 3, 4
• This seroreversion is the exception, not the rule
• The vast majority of patients remain treponemal test-positive lifelong

Clinical Implications

What This Means for Practice:

• Do NOT use treponemal tests (including TP-PA) to monitor treatment response 1, 3
• Treponemal test antibody titers correlate poorly with disease activity 1, 3
• Use nontreponemal tests (RPR/VDRL) quantitatively to assess treatment response and disease activity 1
• A fourfold change in nontreponemal titer (two dilutions) indicates clinically significant change 1

Common Pitfall to Avoid:

Do not repeat treponemal tests like TP-PA to assess cure or treatment response. A persistently positive TP-PA after treatment is expected and normal, not indicative of treatment failure. This represents immunologic memory, not active infection 1, 3.

Diagnostic Algorithm:

1. Screen with either nontreponemal (traditional) or treponemal test (reverse algorithm)
2. Confirm reactive screens with the opposite test type
3. Monitor treatment using only nontreponemal tests (RPR/VDRL) quantitatively
4. Never retest with treponemal tests for treatment monitoring

The TP-PA has demonstrated excellent performance characteristics with sensitivity and specificity comparable to or exceeding other treponemal tests 5, 6, 7, making it a reliable confirmatory test that will remain positive in most treated patients.